CSP has built an innovative, differentiated and late-stage pipeline of products, focused on rare disease and ophthalmology targeting indications with significant unmet needs in China
Rare disease
- China is undergoing dramatic change from a market which ten years ago was broadly focussed on generic drugs to a market where patent protected innovative speciality products are becoming the norm
- 1,423 rare diseases have been identified in China with 20 million rare disease patients with a market potential of $15.5bn USD
- Currently however only about 20% of approved rare disease drugs by the US FDA are approved in China
- Changes to the regulatory environment are seeking to ensure novel speciality products are brought to China within a short window from US/ EMA approval.
- Reimbursement landscape is changing with 2/3 of approved rare disease products in China now being reimbursed. China are currently looking at new models to fund ultra-high cost medicines through commercial insurance plans
Ophthalmology
- Ophthalmology is a huge opportunity and unmet need in China, where the ophthalmology market is growing at an average of around 17.5% a year
- One third of the world’s blindness occurs in China and there is a government initiative to train more ophthalmologists over the next few years
- Changes to the regulatory environment are seeking to ensure novel speciality products are brought to China within a short window from US/ EMA approval.
- Abbreviated clinical development plans can be agreed leveraging clinical data generated in USA/ EU when there is unmet need in China